MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in ...
Pacific Biosciences' Q4'24 results were another disappointment, with revenue and margin misses, and 2025 guidance was notably below expectations. Underlying utilization growth (genetic data ...
With Q4 behind us, let’s have a look at PacBio (NASDAQ:PACB) and its peers. The life sciences tools and services sector supports the research, development, and commercialization of biotechnology ...
Earnings Call Insights: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback